.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
FIDELIO-DKD evaluated the nonsteroidal mineralocorticoid receptor antagonist finerenone in people with type 2 diabetes and chronic kidney disease. Finerenone reduced the risk of kidney disease progression and cardiovascular events compared with placebo on top of optimized renin–angiotensin system blockade. The study is relevant to physicians managing diabetic CKD because residual risk persists even after blood-pressure control and ACE inhibitor or ARB therapy. Finerenone provides an additional pathway targeting mineralocorticoid receptor overactivation while generally causing less gynecomastia than steroidal MRAs. The major practical issue is hyperkalemia, so serum potassium and kidney function require monitoring before and after initiation and dose changes. In practice, therapy should be layered carefully rather than introduced without considering existing medications and electrolyte risk. The trial reinforces a broader principle: diabetic kidney disease now has several evidence-based disease-modifying options, making early identification and systematic risk stratification increasingly important.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
FIDELIO-DKD evaluated the nonsteroidal mineralocorticoid receptor antagonist finerenone in people with type 2 diabetes and chronic kidney disease. Finerenone reduced the risk of kidney disease progression and cardiovascular events compared with placebo on top of optimized renin–angiotensin system blockade. The study is relevant to physicians managing diabetic CKD because residual risk persists even after blood-pressure control and ACE inhibitor or ARB therapy. Finerenone provides an additional pathway targeting mineralocorticoid receptor overactivation while generally causing less gynecomastia than steroidal MRAs. The major practical issue is hyperkalemia, so serum potassium and kidney function require monitoring before and after initiation and dose changes. In practice, therapy should be layered carefully rather than introduced without considering existing medications and electrolyte risk. The trial reinforces a broader principle: diabetic kidney disease now has several evidence-based disease-modifying options, making early identification and systematic risk stratification increasingly important.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
